3.3.2. Proportions of patients experiencing minimal clinically important improvements and declines in HRQoL and work productivity measures by CDC achievement
INFLAMMATORY BOWEL DISEASE, REMISSION, DISEASE
To evaluate the association between CDC achievement and HRQoL, we assessed clinically important improvements from induction baseline to week 10, and clinically important declines from maintenance baseline to week 58, in generic HRQoL and work productivity outcomes. Greater proportions of patients who achieved CDC at week 10 than those who did not achieve CDC experienced minimal clinically important improvements from induction baseline in the following measures: SF-36 PCS, SF-36 MCS and all SF-36 subscale scores, EQ-5D VAS and EQ-5D-5L UK utility scores, and WPAI activity impairment score [all Proportions of patients who experienced minimal clinically important improvements from induction baseline to week 10 and minimal clinically important declines from maintenance baseline to week 58 in SF-36, EQ-5D and WPAI scores, among CDC achievers and non-achievers
CDC was defined as achievement of pMCS remission, endoscopic improvement, inflammatory biomarker remission and IBDQ remission.CDC, Comprehensive Disease Control; EQ-5D, EuroQol 5-dimension; EQ-5D-5L, EuroQol 5-dimension 5-level; HRQoL, health-related quality of life; IBDQ, Inflammatory Bowel Disease Questionnaire; MCID, minimal clinically important difference; MCS, mental component summary; PCS, physical component summary; pMCS, partial Mayo Clinic Score; SF-36, 36-Item Short-Form Survey; VAS, visual analogue scale, WPAI, Work Productivity and Activity Impairment questionnaire.